Feng Chi Biotech Corp. (6744) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Feng Chi Biotech Corp. TWD 11.99, price TWD 14.40, upside -16.7%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Feng Chi Biotech Corp. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 13.27 TWD – 25.74 TWD · fair‑value band 8.73 TWD – 13.25 TWD · the 14.40 TWD price screens above the 11.99 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Feng Chi Biotech in your weekly email
Every Wednesday you see whether Feng Chi Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Feng Chi Biotech Corp. engages in the wholesale and retail of medical equipment and precision instruments and biotechnology services in Taiwan and internationally.
Show more
Feng Chi Biotech Corp. engages in the wholesale and retail of medical equipment and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various genetic testing technologies and products in oncology. The company was founded in 1992 and is based in Taipei, Taiwan.
Stock analysis
Feng Chi Biotech Corp. (6744) currently trades at 14.40 TWD, while our model-based Fair Value estimate is 11.99 TWD, implying the stock looks roughly 20.1% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 15.98 TWD per share, and 6 of the 15 models we run sit above the 14.40 TWD price.
Bear case: the Earnings-Based group reads lowest at 8.04 TWD, and 9 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: 8.73 TWD (bear) to 13.25 TWD (bull), the price of 14.40 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Feng Chi Biotech Corp. reported revenue of 177M TWD in FY2025 versus 183M TWD in FY2021, a compound −0.7%/yr. Reported net income was 14.5M TWD in FY2025, compounding −11.1%/yr from FY2021.
Key figures
Market cap 222M TWD (≈ $7.0M) · P/E ratio 15.3 · P/S ratio 1.25 · EPS (TTM) 0.9400 TWD · Dividend yield 6.3% · Net margin 8.2% · Return on equity 6.0% · Return on assets (EBIT) 7.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −17%, 6744 screens richer than that median.
Fair Value models
Bear 8.73 TWDFair Value 11.99 TWDBull 13.25 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.6902 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.24/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−2.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.9%
Dividend (yield on the price)6.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 8%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside−17% · Above median
Profitability
Return on equity (TTM)6% · Above median
Return on assets3% · Top 25%
Net margin (TTM)8% · Above median
Operating margin (TTM)5% · Above median
Growth and dividend
Revenue growth−3% · Below median
Dividend yield (TTM)6.3% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Feng Chi Biotech Corp. Fair Value". https://www.fairvalue-calculator.com/stock/6744
Frequently asked questions
Is Feng Chi Biotech Corp. (6744) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 11.99 TWD versus a price of 14.40 TWD, about −17% upside (overvalued).
What is the fair value of 6744?
Our model-based fair value for Feng Chi Biotech Corp. is 11.99 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 14.40 TWD.
What is the quality score of 6744?
Feng Chi Biotech Corp. has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Feng Chi Biotech Corp. (6744)?
Our model-based price target is the fair value of 11.99 TWD (as of Sep 24, 2026) from 15 valuation models. Cautious scenario 8.73 TWD, optimistic scenario 13.25 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Feng Chi Biotech Corp. stock forecast for 2026?
Our models put fair value at 11.99 TWD, about −17% upside versus a price of 14.40 TWD (overvalued). Cautious scenario 8.73 TWD, optimistic scenario 13.25 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Feng Chi Biotech Corp. (6744)?
Feng Chi Biotech Corp. reported trailing-twelve-month revenue of about 177M TWD (latest available figure, as of Sep 24, 2026).
Does Feng Chi Biotech Corp. pay a dividend?
Feng Chi Biotech Corp. currently shows a dividend yield of about 6.25% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Feng Chi Biotech Corp. (6744)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Feng Chi Biotech Corp. it is 11.99 TWD per share (as of Sep 24, 2026), against a price of 14.40 TWD. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Feng Chi Biotech Corp. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6744 trades above its calculated fair value: price 14.40 TWD, fair value 11.99 TWD, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6744?
No. The price is what the market pays today (14.40 TWD); the fair value is what the company's own numbers justify (11.99 TWD). For Feng Chi Biotech Corp. the two are 2.41 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Feng Chi Biotech Corp. worth?
The market values Feng Chi Biotech Corp. at about 222M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 14.40 TWD; our models calculate a fair value of 11.99 TWD per share.
What do the bullish and bearish scenarios say about 6744?
Our models span a range for Feng Chi Biotech Corp.: cautious scenario 8.73 TWD, base 11.99 TWD, optimistic 13.25 TWD per share (as of Sep 24, 2026, price 14.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6744?
Feng Chi Biotech Corp. trades at a price-to-earnings ratio of 15.3 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 11.99 TWD is built from several models across several years. Other multiples: P/B 0.9, P/S 1.3, EV/EBITDA 8.8.
How solid is the balance sheet of Feng Chi Biotech Corp. (6744)?
Balance-sheet figures for Feng Chi Biotech Corp. (as of Sep 24, 2026): return on equity 6.0%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 6744 from its 52-week high?
Feng Chi Biotech Corp. trades at 14.40 TWD, about 25% below its 52-week high of 19.24 TWD and 9% above the low of 13.27 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 11.99 TWD is for.
Which stocks are comparable to Feng Chi Biotech Corp.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Feng Chi Biotech Corp. stock attractive at the current price?
The data as of Sep 24, 2026: price 14.40 TWD, calculated fair value 11.99 TWD (−17%), Quality Score 55/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6744 calculated?
We run Feng Chi Biotech Corp. through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 11.99 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Feng Chi Biotech Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Feng Chi Biotech Corp. (6744)?
The closing price on Sep 24, 2026 was 14.40 TWD. Our model-based fair value is 11.99 TWD, about −17% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Feng Chi Biotech Corp. right now?
The price sits above even our optimistic bull case (13.25 TWD). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Feng Chi Biotech Corp.
How large is the market capitalisation of Feng Chi Biotech Corp. (6744)?
The market capitalisation of Feng Chi Biotech Corp. is 222M TWD (≈ $7.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Feng Chi Biotech Corp. (6744)?
The price-to-sales ratio of Feng Chi Biotech Corp. is 1.25 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Feng Chi Biotech Corp. (6744)?
Earnings per share at Feng Chi Biotech Corp. are 0.9400 TWD (price ÷ EPS = P/E 15.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Feng Chi Biotech Corp. (6744)?
The dividend yield of Feng Chi Biotech Corp. is 6.3% (payout 95.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Feng Chi Biotech Corp. (6744)?
The net margin of Feng Chi Biotech Corp. is 8.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Feng Chi Biotech Corp. (6744)?
The return on equity (ROE) of Feng Chi Biotech Corp. is 6.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Feng Chi Biotech Corp. (6744)?
On an EBIT basis the return on assets of Feng Chi Biotech Corp. is 7.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Feng Chi Biotech Corp. (6744)?
The operating margin of Feng Chi Biotech Corp. is 4.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Feng Chi Biotech Corp. (6744)?
Revenue at Feng Chi Biotech Corp. is growing −3.1% versus a year earlier (3y avg −2.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Feng Chi Biotech Corp. (6744)?
Earnings per share at Feng Chi Biotech Corp. are growing −16.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Feng Chi Biotech Corp. (6744) generate?
The free cash flow of Feng Chi Biotech Corp. is −9.9M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Feng Chi Biotech Corp. (6744) hold?
Feng Chi Biotech Corp. holds more cash than debt, 18.1M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Feng Chi Biotech Corp. in the live analysis
One click puts Feng Chi Biotech Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
